Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.8
1 Year Target Price $9.8
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.17% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.49M USD | Price to earnings Ratio - | 1Y Target Price 9.8 |
Price to earnings Ratio - | 1Y Target Price 9.8 | ||
Volume (30-day avg) 4 | Beta 1.6 | 52 Weeks Range 1.43 - 3.98 | Updated Date 09/16/2025 |
52 Weeks Range 1.43 - 3.98 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -174.67% | Operating Margin (TTM) -1484.53% |
Management Effectiveness
Return on Assets (TTM) -14.64% | Return on Equity (TTM) -50.98% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 90936320 | Price to Sales(TTM) 8.63 |
Enterprise Value 90936320 | Price to Sales(TTM) 8.63 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100600000 | Shares Floating 39960717 |
Shares Outstanding 100600000 | Shares Floating 39960717 | ||
Percent Insiders 38.01 | Percent Institutions 24.72 |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune SA is a Swiss-based clinical-stage biopharmaceutical company founded in 2003. It focuses on developing therapies and diagnostics for neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. It went public via an IPO on the Nasdaq in 2016.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Focuses on developing antibodies and small molecules targeting amyloid beta, tau, and alpha-synuclein pathologies associated with Alzheimer's and Parkinson's diseases.
- Diagnostics: Develops diagnostic tools for early detection and monitoring of neurodegenerative diseases.
- Partnering: Collaborates with pharmaceutical companies to advance its drug candidates through clinical development and commercialization.
Leadership and Structure
The company is led by a CEO and a management team with expertise in drug development and neuroscience. The organizational structure includes research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- Crenezumab (Partnered with Roche):: A monoclonal antibody targeting aggregated amyloid beta. It's in clinical development for early Alzheimer's disease. Roche holds the primary market share responsibility. Competitors include Biogen's Aduhelm and Eisai/Biogen's Leqembi.
- ACI-35.030 (Anti-pTau vaccine): A vaccine targeting phosphorylated tau protein, a key pathological marker in Alzheimer's disease. It's in clinical development. Competitors in the Tau space include other vaccine and antibody developers such as Biogen.
- ACI-12589 (Small molecule alpha-synuclein inhibitor): A small molecule inhibitor of alpha-synuclein aggregation for Parkinson's disease. It's in preclinical development. Other companies working in the alpha-synuclein space include Biogen and Roche.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to the aging global population. It is characterized by high unmet medical needs and intense competition.
Positioning
AC Immune positions itself as a leader in developing innovative therapies targeting the underlying causes of neurodegenerative diseases. Its competitive advantages include its proprietary technology platforms and partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of USD. AC Immune is positioned to capture a portion of this market through its pipeline of therapeutic candidates.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Strong partnerships with Roche and other pharmaceutical companies
- Diverse pipeline of therapeutic candidates
- Experienced management team
Weaknesses
- High development risk associated with clinical trials
- Dependence on partners for funding and commercialization
- Limited commercial infrastructure
- Historically has had cash flow issues
Opportunities
- Advancements in early disease detection
- Increasing regulatory support for Alzheimer's therapies
- Expansion of partnerships and collaborations
- Potential for breakthrough therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- RHHBY
Competitive Landscape
AC Immune competes with larger pharmaceutical companies with greater resources. Its competitive advantage lies in its innovative technology platforms and specific targeting of neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its pipeline and collaborations. It relies heavily on the success of their drugs to improve the financial success of the company.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals of its lead drug candidates. Analyst projections are variable but depend on the clinical trial success.
Recent Initiatives: Recent initiatives include advancing its pipeline of therapeutic candidates into clinical development and expanding its partnerships.
Summary
AC Immune is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Their technology platforms and strategic partnerships are strengths, but high development risk and dependence on partners pose challenges. Future success hinges on clinical trial outcomes and regulatory approvals, but recent advancements and initiatives suggest growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AC Immune website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.